Drug Trial Radar · NCT04868981
Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets
Last checked: Nov 20, 2026Latest source record: Jun 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 31, 2021
Primary completion
Feb 23, 2022
Study completion Mar 14, 2022
Sponsor
- Lead sponsor
- Fujian Cosunter Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)
Conditions
- Hepatitis B
Interventions
GST-HG141 tabletsDrug
Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Matching Placebos for GST-HG141 tabletsDrug
Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities.Time frame: Up to 33 days
- Cmax of GST-HG141Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
- AUC of GST-HG141Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
- t1/2 of GST-HG141Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
- Cl/F of GST-HG141Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.